reglab/housing_qa huggingface dataset:
IN Code § 16-42-24-4 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 24. Drugs: Use of Chymopapain|16-42-24-4. Disciplinary Action Against Attending Physician Prohibited if Use Requested by Patient

     Revisor's Note: The version of IC 16-42-24-4 appearing in the 1993 Edition of the Indiana Code was printed incorrectly. Use the following version of IC 16-42-24-4.Sec. 4. A neurosurgeon or an orthopedic surgeon may not be subjected to disciplinary action by the medical licensing board of Indiana for administering chymopapain to a patient under the neurosurgeons's or orthopedic surgeon's care to treat certain back ailments if the patient has signed the request form described in section 7 of this chapter.[Pre-1993 Recodification Citation: 16-8-10-2.]As added by P.L.2-1993, SEC.25.
IN Code § 16-42-24-5 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 24. Drugs: Use of Chymopapain|16-42-24-5. Use Permitted in Place of Other Therapies if Requested by Patient

Sec. 5. A neurosurgeon or an orthopedic surgeon may administer chymopapain instead of other modes of therapy for treatment of certain back ailments of a patient who has signed the request form described in section 7 of this chapter.[Pre-1993 Recodification Citation: 16-8-10-3.]As added by P.L.2-1993, SEC.25.
IN Code § 16-42-24-6 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 24. Drugs: Use of Chymopapain|16-42-24-6. Construction of Chapter

Sec. 6. This chapter is not an endorsement of chymopapain for the treatment of back ailments.[Pre-1993 Recodification Citation: 16-8-10-4.]As added by P.L.2-1993, SEC.25.
IN Code § 16-42-24-7 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 24. Drugs: Use of Chymopapain|16-42-24-7. Use Request Form

Sec. 7. (a) The state department shall prepare a form for a patient to use to request administration of chymopapain. The form must be substantially in the following form:
IN Code § 16-42-24-8 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 24. Drugs: Use of Chymopapain|16-42-24-8. Regulation of Manufacture, Distribution, Sale, or Use

Sec. 8. (a) Chymopapain is not a drug or a controlled substance under Indiana statutes governing the use, manufacture, or distribution of drugs and controlled substances within Indiana.(b) The state department and the Indiana board of pharmacy may regulate the manufacture, distribution, and sale of chymopapain for use within Indiana only to ensure that the substance is not adulterated or misbranded within the meaning of IC 16-42-3.(c) The state department may not adopt a rule that prohibits the use of chymopapain in a hospital or health care facility licensed by the state department.(d) The Indiana board of pharmacy may not adopt a rule that prohibits the manufacture, distribution, or sale of chymopapain by a person or in a place licensed by the Indiana board of pharmacy.[Pre-1993 Recodification Citation: 16-8-10-6.]As added by P.L.2-1993, SEC.25.
IN Code § 16-42-24-9 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 24. Drugs: Use of Chymopapain|16-42-24-9. Manufacture, Sale, Distribution, or Prescription Not Required

Sec. 9. (a) This chapter does not require a:(1) physician;(2) pharmacist;(3) pharmacy;(4) manufacturer; or(5) distributor;to manufacture, sell, or distribute chymopapain.(b) This chapter does not require a physician to prescribe chymopapain for a patient.[Pre-1993 Recodification Citation: 16-8-10-7(a).]As added by P.L.2-1993, SEC.25.
IN Code § 16-42-24-10 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 24. Drugs: Use of Chymopapain|16-42-24-10. Use Prohibition by Health Care Facility Facing Loss of Federal Funding

Sec. 10. If:(1) the federal government indicates that the federal government will withdraw all federal funds from a health care facility for allowing chymopapain to be used within the facility; and(2) providing or allowing use of chymopapain within the facility would jeopardize the receipt of:(A) federal funds for reimbursement for Medicare or Medicaid for all persons within the facility; or(B) construction funds provided by the federal government under the Hill-Burton Hospital Construction Program (42 U.S.C. 291 et seq.) or under Title XVI of the Public Health Services Act (42 U.S.C. 300q-300t);the hospital or other health care facility may prohibit the use of chymopapain within the hospital or facility.[Pre-1993 Recodification Citation: 16-8-10-7(b).]As added by P.L.2-1993, SEC.25.
IN Code § 16-42-25-1 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 25. Drugs: Biosimilar Biological Products|16-42-25-1. "Biological Product"

Sec. 1. As used in this chapter, "biological product" means:(1) a virus;(2) a therapeutic serum;(3) a toxin;(4) an antitoxin;(5) a vaccine;(6) blood;(7) a blood component;(8) a blood derivative;(9) an allergenic product;(10) a protein (except any chemically synthesized polypeptide);(11) a product analogous to a product described in subdivisions (1) through (10);(12) arsphenamine;(13) an arsphenamine derivative; or(14) any other trivalent organic arsenic compound;applicable to the prevention, treatment, or cure of a disease or condition for human beings.As added by P.L.96-2014, SEC.6.
IN Code § 16-42-25-2 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 25. Drugs: Biosimilar Biological Products|16-42-25-2. "Biosimilar"

Sec. 2. As used in this chapter, "biosimilar" refers to a biological product that:(1) has been licensed as a biosimilar product under 41 U.S.C. 262(k) or has been approved based on an application filed under 21 U.S.C. 355(b)(2); and(2) is highly similar to the reference product, with:(A) no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency of the product; and(B) only minor differences in clinically inactive components.As added by P.L.96-2014, SEC.6.
IN Code § 16-42-25-3 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 25. Drugs: Biosimilar Biological Products|16-42-25-3. "Interchangeable"

Sec. 3. As used in this chapter, "interchangeable" means:(1) a determination by the federal Food and Drug Administration that a biosimilar product may be substituted for a reference biological product without the intervention of the health care provider that prescribed the biological product; or(2) concerning a biological product filed under 21 U.S.C. 355(b)(2), a product that is designated as therapeutically equivalent by the federal Food and Drug Administration in the Approved Drug Products with Therapeutic Equivalence Evaluations.As added by P.L.96-2014, SEC.6.
IN Code § 16-42-25-4 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 25. Drugs: Biosimilar Biological Products|16-42-25-4. Substitution; Conditions

Sec. 4. A pharmacist may substitute for a prescribed biological product if the following conditions are met:(1) The substitute has been determined by the federal Food and Drug Administration to be interchangeable with the prescribed biological product.(2) The prescribing practitioner has:(A) for a written prescription, signed on the line under which the words "May substitute." appear; or(B) for an electronically transmitted prescription, electronically transmitted the instruction "May substitute.".(3) The pharmacist has informed the customer of the substitution.As added by P.L.96-2014, SEC.6.
IN Code § 16-42-25-5 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 25. Drugs: Biosimilar Biological Products|16-42-25-5. Records of Dispensing Biologic Product; Time Frame; Exception

Sec. 5. (a) Except as provided in subsection (b), in order to ensure medical records are complete and accurate, a pharmacist shall, not later than ten (10) calendar days after dispensing a biologic product, record the name and manufacturer of the biologic product dispensed using:(1) an interoperable electronic health records system shared with the prescribing practitioner, to the extent a system is in place between the pharmacist and the practitioner; or(2) if an electronic health records system is not in place between the pharmacist and the prescribing practitioner, any prevailing means available to communicate to the prescribing practitioner the name and manufacturer of the biologic product dispensed.(b) The pharmacist is not required to report to or communicate with the prescribing practitioner under subsection (a)(2) if:(1) there is no federal Food and Drug Administration approved interchangeable biological product for the prescribed biological product; or(2) the refill prescription is not changed from the product originally dispensed.As added by P.L.96-2014, SEC.6.
IN Code § 16-42-25-6 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 25. Drugs: Biosimilar Biological Products|16-42-25-6. Record Retention; Pharmacy; Prescribing Practitioner

Sec. 6. (a) The pharmacy shall retain a record in accordance with IC 25-26-13-25(a) of the dispensed biological product.(b) The prescribing practitioner shall retain a record in accordance with IC 16-39-7-1 of the dispensed biological product.As added by P.L.96-2014, SEC.6.
IN Code § 16-42-25-7 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 25. Drugs: Biosimilar Biological Products|16-42-25-7. Link to Current List of Interchangeable Biological Products; Rules

Sec. 7. (a) The Indiana board of pharmacy shall maintain a link on the board's Internet web site to the current list of all biological products determined by the United States Food and Drug Administration to be interchangeable with a specific reference biological product.(b) The Indiana board of pharmacy may adopt rules under IC 4-22-2 necessary to implement this chapter.As added by P.L.96-2014, SEC.6.
IN Code § 16-42-25-8 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 25. Drugs: Biosimilar Biological Products|16-42-25-8. Compliance With Prescription Requirements

Sec. 8. A written or electronic prescription for a biological product must comply with the requirements under IC 16-42-22-6.As added by P.L.96-2014, SEC.6.
IN Code § 16-42-26-1 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 26. Drugs: Investigational Drug, Biological Product, or Device|16-42-26-1. Effect on Clinical Trial Laws; Availability

Sec. 1. (a) This chapter does not affect IC 5-10-8-15, IC 12-15-5-9.2, IC 27-8-25, or IC 27-13-7-20.2.(b) This chapter does not require a manufacturer to make available any investigational drug, biological product, or device.As added by P.L.2-2015, SEC.3.
IN Code § 16-42-26-2 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 26. Drugs: Investigational Drug, Biological Product, or Device|16-42-26-2. "Investigational Drug, Biological Product, or Device"

Sec. 2. As used in this chapter, "investigational drug, biological product, or device" means an investigational or experimental:(1) drug;(2) biological product; or(3) medical device;that has successfully completed Phase I of a federal Food and Drug Administration approved clinical trial, but has not been approved for general use by the federal Food and Drug Administration and remains under investigation in a clinical trial.As added by P.L.2-2015, SEC.3.
IN Code § 16-42-26-3 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 26. Drugs: Investigational Drug, Biological Product, or Device|16-42-26-3. "Qualified Patient"

Sec. 3. As used in this chapter, "qualified patient" means a patient who meets the requirements under IC 25-22.5-1-2.1(a).As added by P.L.2-2015, SEC.3.
IN Code § 16-42-26-4 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 26. Drugs: Investigational Drug, Biological Product, or Device|16-42-26-4. Availability of Investigational Drug, Biological Product, or Device

Sec. 4. (a) A manufacturer of an investigational drug, biological product, or device may make available the investigational drug, biological product, or device to a qualified patient.(b) A manufacturer may do any of the following:(1) Provide an investigational drug, biological product, or device to a qualified patient without receiving compensation.(2) Require a qualified patient to pay the costs of or associated with the manufacture of the investigational drug, biological product, or device.As added by P.L.2-2015, SEC.3.
IN Code § 16-42-26-5 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 26. Drugs: Investigational Drug, Biological Product, or Device|16-42-26-5. Causes of Action

Sec. 5. This chapter does not create a cause of action against a manufacturer of an investigational drug, biological product, or device for any harm to a qualified patient resulting from use of an investigational drug, biological product, or device.As added by P.L.2-2015, SEC.3.
IN Code § 16-42-27-1 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 27. Drugs: Overdose Intervention Drugs|16-42-27-1. "Prescriber"

Sec. 1. As used in this chapter, "prescriber" means any of the following:(1) A physician licensed under IC 25-22.5.(2) A physician assistant licensed under IC 25-27.5 and granted the authority to prescribe by the physician assistant's collaborating physician and in accordance with IC 25-27.5-5-4.(3) An advanced practice registered nurse licensed and granted the authority to prescribe drugs under IC 25-23.(4) The state health commissioner, if the state health commissioner holds an active license under IC 25-22.5.(5) A public health authority.As added by P.L.32-2015, SEC.7. Amended by P.L.6-2016, SEC.5; P.L.129-2018, SEC.21; P.L.247-2019, SEC.1.
IN Code § 16-42-27-3 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 27. Drugs: Overdose Intervention Drugs|16-42-27-3. Immunity of Provider, Pharmacist, Individual, Entity

Sec. 3. (a) Except for an act of gross negligence or willful misconduct, a prescriber who dispenses or prescribes an overdose intervention drug in compliance with this chapter is immune from civil liability arising from those actions.(b) Except for an act of gross negligence or willful misconduct, a pharmacist who dispenses an overdose intervention drug in compliance with this chapter is immune from civil liability arising from those actions.(c) Except for an act of gross negligence or willful misconduct, an individual or entity described in section 2(a)(1) of this chapter is immune from civil liability for the following actions:(1) Obtaining an overdose intervention drug under this chapter.(2) Administering an overdose intervention drug in good faith.(3) Acting under a standing order under this chapter.As added by P.L.32-2015, SEC.7.
IN Code § 16-44-1-1 (2021)
2021 Indiana Code|Title 16. Health|Article 44. Product Labeling and Inspection|Chapter 1. Labeling of Used or Reclaimed Lubricating Oil|16-44-1-1. Labeling Requirements; Advertisements; Violations

Sec. 1. (a) A person who deals in retail in:(1) previously used or previously used and reclaimed;(2) refined;(3) recleaned; or(4) reconditioned:lubricating oils, lubricants, or mixtures of lubricants shall at all times have every container or item of equipment in or through which any of those products are sold, kept for sale, displayed, or dispensed plainly labeled under subsection (b).(b) The products described in subsection (a) must be plainly labeled in lettering:(1) as large as any other lettering on the product; or(2) in letters at least one-half (1/2) inch in height;whichever is larger, stating that the contents comprise a previously used product.(c) A person who publishes, displays, or circulates an advertisement offering for sale any:(1) previously used or previously used and reclaimed;(2) rerefined;(3) recleaned; or(4) reconditioned;lubricating oils, lubricants, or mixtures of lubricants shall state in the advertisement, in letters at least as large as any other lettering in the advertisement, the fact that the products have been previously used.(d) A person who recklessly violates this section commits a Class B misdemeanor.[Pre-1993 Recodification Citation: 16-6-10-1.]As added by P.L.2-1993, SEC.27.
IN Code § 16-44-1-2 (2021)
2021 Indiana Code|Title 16. Health|Article 44. Product Labeling and Inspection|Chapter 1. Labeling of Used or Reclaimed Lubricating Oil|16-44-1-2. Injunction

Sec. 2. (a) A person who deals at retail:(1) in:(A) previously used or previously used and reclaimed;(B) refined;(C) recleaned; or(D) reconditioned;lubricating oils, lubricants, or mixtures of lubricants; and(2) without:(A) plainly labeling, as required by this chapter, each container or item of equipment in or through which any of the products described in subdivision (1) are sold, kept for sale, displayed, or dispensed; or(B) inserting in any advertisement of those products a statement required by this chapter that the products have been previously used, reclaimed, rerefined, recleaned, or reconditioned;may be enjoined from selling or offering, displaying, or advertising for sale any of the products described in subdivision (1).(b) An action for an injunction under this section may be brought in any court having jurisdiction to hear and decide cases in the county in which the defendant resides. The action for an injunction may be brought by the following:(1) The attorney general.(2) The prosecuting attorney for the county.(c) The authority granted by this section is in addition to the authority to criminally prosecute a person for a violation of this chapter.[Pre-1993 Recodification Citation: 16-6-10-2 part.]As added by P.L.2-1993, SEC.27.
IN Code § 16-44-1-3 (2021)
2021 Indiana Code|Title 16. Health|Article 44. Product Labeling and Inspection|Chapter 1. Labeling of Used or Reclaimed Lubricating Oil|16-44-1-3. Temporary Injunction; Prohibition; Right to Hearing

Sec. 3. This chapter does not confer upon any court the right to grant temporary restraining orders or temporary injunctions under this chapter, and an injunction may not be issued until the defendant has had a day in court.[Pre-1993 Recodification Citation: 16-6-10-2 part.]As added by P.L.2-1993, SEC.27.
IN Code § 16-44-1-4 (2021)
2021 Indiana Code|Title 16. Health|Article 44. Product Labeling and Inspection|Chapter 1. Labeling of Used or Reclaimed Lubricating Oil|16-44-1-4. Injunction; Purpose

Sec. 4. (a) The granting or enforcing of an injunction under this chapter is a preventive measure for the protection of the people of this state, not a punitive measure.(b) The fact that a person has been charged or convicted of a violation of this chapter does not prevent the issuance of an injunction to prevent further unlawful dealing in previously used, reclaimed, rerefined, recleaned, or reconditioned lubricating oils, lubricants, or mixtures of lubricants.(c) The fact that an injunction has been granted under this chapter does not preclude criminal prosecution.[Pre-1993 Recodification Citation: 16-6-10-2 part.]As added by P.L.2-1993, SEC.27.
IN Code § 16-44-2-1 (2021)
2021 Indiana Code|Title 16. Health|Article 44. Product Labeling and Inspection|Chapter 2. Inspection, Sale, and Delivery of Petroleum Products|16-44-2-1. "Gasoline" Defined

Sec. 1. As used in this chapter, "gasoline" has the meaning set forth in IC 6-6-1.1-103.[Pre-1993 Recodification Citation: 16-6-11-1(e).]As added by P.L.2-1993, SEC.27.
IN Code § 16-44-2-2 (2021)
2021 Indiana Code|Title 16. Health|Article 44. Product Labeling and Inspection|Chapter 2. Inspection, Sale, and Delivery of Petroleum Products|16-44-2-2. "Kerosene" Defined

Sec. 2. As used in this chapter, "kerosene" means any light fuel oil:(1) with an A.P.I. gravity of at least thirty-nine (39) degrees Fahrenheit as determined by the ASTM D-287-55 method; and(2) having an end point of not greater than five hundred ninety (590) degrees Fahrenheit as determined by the ASTM D-86-56 distillation method.[Pre-1993 Recodification Citation: 16-6-11-1(f).]As added by P.L.2-1993, SEC.27. Amended by P.L.177-1993, SEC.3.
IN Code § 16-44-2-2.4 (2021)
2021 Indiana Code|Title 16. Health|Article 44. Product Labeling and Inspection|Chapter 2. Inspection, Sale, and Delivery of Petroleum Products|16-44-2-2.4. "Mtbe" Defined

Sec. 2.4. As used in this chapter, "MTBE" refers to the gasoline additive methyl tertiary butyl ether.As added by P.L.26-2002, SEC.2.
IN Code § 16-44-2-3 (2021)
2021 Indiana Code|Title 16. Health|Article 44. Product Labeling and Inspection|Chapter 2. Inspection, Sale, and Delivery of Petroleum Products|16-44-2-3. "Petroleum Products" Defined

Sec. 3. (a) As used in this chapter, "petroleum products" includes the following:(1) Gasoline.(2) Naphtha.(3) Kerosene.(4) Distillate.(5) Fuel oil.(6) Similar petroleum products, regardless of name, including benzol and other similar products that are or may be used in the blending of motor fuel.(b) The term does not include the following:(1) Lubricating oils.(2) Any product having:(A) a Saybolt universal viscosity at one hundred (100) degrees Fahrenheit of at least seventy (70) seconds; and(B) a flash point of at least one hundred fifty (150) degrees Fahrenheit by the ASTM method.[Pre-1993 Recodification Citation: 16-6-11-1(a).]As added by P.L.2-1993, SEC.27.
IN Code § 16-44-2-4 (2021)
2021 Indiana Code|Title 16. Health|Article 44. Product Labeling and Inspection|Chapter 2. Inspection, Sale, and Delivery of Petroleum Products|16-44-2-4. Gasoline and Kerosene for Sale or Use in Indiana; Inspection of Samples; Fee

Sec. 4. (a) The state department or any authorized agent of the state department may inspect samples of gasoline or kerosene stored in any tank:(1) that is adjacent to a refinery or marine or pipeline terminal in Indiana; and(2) from which withdrawals are made for sale or use in Indiana or for transportation to destinations in Indiana other than transportation to other refineries or terminals in Indiana.(b) Gasoline or kerosene inspected under subsection (a) is subject to the inspection fee specified in section 18 of this chapter whenever the stock in the tank is replenished.[Pre-1993 Recodification Citation: 16-6-11-3(a).]As added by P.L.2-1993, SEC.27. Amended by P.L.177-1993, SEC.4.
IN Code § 16-44-2-5 (2021)
2021 Indiana Code|Title 16. Health|Article 44. Product Labeling and Inspection|Chapter 2. Inspection, Sale, and Delivery of Petroleum Products|16-44-2-5. Imported Gasoline and Kerosene; Inspection of Samples; Fee

Sec. 5. (a) The state department or any authorized agent of the state department may inspect samples of gasoline or kerosene imported into Indiana other than that placed in storage at refineries or marine or pipeline terminals in Indiana.(b) Gasoline or kerosene inspected under subsection (a) is subject to the inspection fee specified in section 18 of this chapter.(c) A person who receives gasoline or kerosene:(1) that is imported into Indiana (other than that placed in storage at refineries or marine or pipeline terminals in Indiana); and(2) on which the inspection fee has not been paid;shall notify the state department of the receipt of the gasoline or kerosene.[Pre-1993 Recodification Citation: 16-6-11-3(b).]As added by P.L.2-1993, SEC.27. Amended by P.L.177-1993, SEC.5.